SCHEMBL25810563

SCHEMBL25810563

CC(C)(C)OC(=O)CN1CCC(n2cc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.43
WNT1 P04628 1/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
USP30 Q70CQ3 2/20 0.40
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
DGAT1 O75907 1/20 0.33
HTR4 Q13639 1/20 0.33
MET P08581 2/20 0.33
BACE1 P56817 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
AAK1 Q2M2I8 1/20 0.32
CCNC P24863 1/20 0.32
CDK8 P49336 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR4 P22455 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25810466 0.94 FFAR1 (0.42) FFAR1WNT1GSK3BDYRK1AUSP30
SCHEMBL25810566 0.90 FFAR1 (0.42) FFAR1WNT1GSK3BDYRK1AUSP30
SCHEMBL25292939 0.87 FFAR1 (0.39) FFAR1WNT1GSK3BDYRK1AUSP30
SCHEMBL25810492 0.87 FFAR1 (0.40) FFAR1WNT1GSK3BDYRK1AUSP30
SCHEMBL320828 0.85 USP30 (0.52) FFAR1USP30DDB1CRBNMET
SCHEMBL25253927 0.84 USP30 (0.40) FFAR1WNT1GSK3BDYRK1AUSP30
SCHEMBL25248743 0.83 DDB1 (0.45) FFAR1USP30DDB1CRBNCCNC
SCHEMBL1581816 0.83 FFAR1 (0.41) FFAR1USP30DDB1CRBNPRMT5
SCHEMBL25291152 0.82 FFAR1 (0.43) FFAR1WNT1GSK3BDYRK1AUSP30
SCHEMBL26106789 0.82 FFAR1 (0.47) FFAR1GSK3BDYRK1AUSP30DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 US disclosed
EP-4452978-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 EP disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 FFAR1 1395/4885WNT1 1463/4885GSK3B 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.